Masimo Corp

Masimo Corp(MASI)の株式分析

$179.950

+0.018 (+0.01%)終値時点

Loading chart…
高値
179.990
始値
179.950
出来高加重平均価格
179.96
出来高
3.16M
時価総額
6.99B
安値
179.950
売買代金
568.70M
EV/EBITDA(TTM)
21.69

Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.

www.masimo.com

AI分析 of Masimo Corp (MASI)

売り

Masimo is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is already trading essentially at the acquisition offer level around $180, which leaves very limited upside. Given the pre-market price of 179.95, the best risk/reward is poor for a fresh entry, and the situation is more of a merger-arbitrage hold than a long-term accumulation opportunity. For an impatient investor who does not want to wait for a better entry, this is a sell/no-buy setup rather than a buy.

アナリスト評価(6)

上値余地 +4.70%
買い
3 買い
3 中立
0 売り
現在: 179.95
安値
162.00
平均
188.40
高値
210.00

Raymond James

2026-03-27

目標株価

$180

Market Perform

Wells Fargo

2026-03-18

目標株価

$180

Equal Weight

Wells Fargo

2025-12-05

目標株価

$190

オーバーウェイト

BTIG

2025-12-04

目標株価

$200

買い

BofA

2025-11-17

目標株価

$162

中立

バリュエーション指標

Masimo Corp(MASI)の現在の予想PERは40.82で、5年平均は35.46です。

予想PER

適正
5年平均 P/E
35.46
現在のP/E
40.82
割高
45.39
割安
25.53

予想EV/EBITDA

適正
5年平均 EV/EBITDA
20.90
現在のEV/EBITDA
21.69
割高
26.92
割安
14.89

予想PSR

適正
5年平均 P/S
4.42
現在のP/S
5.39
割高
6.43
割安
2.41

Alphio AI による MASI の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%MASI

$166.97

シナリオ価格

基

基本

基本 · 50%MASI

$159.11

シナリオ価格

弱

弱気

弱気 · 25%MASI

$157.95

シナリオ価格

MASI を保有するクジラ

S

Sofinnova Investments, Inc.

+ を保有MASI

+7.79%

3か月リターン

A

Alyeska Investment Group, L.P.

+ を保有MASI

+2.53%

3か月リターン

W

Westfield Capital Management Company, L.P.

+ を保有MASI

-2.57%

3か月リターン

R

RTW Investments, LP

+ を保有MASI

-11.31%

3か月リターン

MASI のよくある質問 — Alphio AI が回答

Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Masimo is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is already trading essentially at the acquisition offer level around $180, which leaves very limited upside. Given the pre-market price of 179.95, the best risk/reward is poor for a fresh entry, and the situation is more of a merger-arbitrage hold than a long-term accumulation opportunity. For an impatient investor who does not want to wait for a better entry, this is a sell/no-buy setup rather than a buy.

6 analysts cover MASI: 3 rate it Buy, 3 Hold and 0 Sell. The average price target is 188.40.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める